DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: argatroban
|
Tentative approvals for ARGATROBAN
| ||||||||||||||||||||||
Clinical Trials for: argatrobanRandomized Controlled Trial of Argatroban With tPA for Acute Stroke Status: Recruiting Condition: Ischemic Stroke Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting Status: Recruiting Condition: CVD Argatroban Versus Lepirudin in Critically Ill Patients Status: Terminated Condition: Heparin Induced Thrombocytopenia (HIT) Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI) Status: Completed Condition: Coronary Artery Disease; Angina, Unstable Argatroban in Critically Ill Patients With Heparin Resistance Status: Recruiting Condition: Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion Status: Terminated Condition: Coronary Artery Bypass Graft Surgery; Presence of Heparin/Platelet Factor 4 Antibody Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||||||||||||||
Litigation for: ARGATROBAN | |||||||||||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | ARGATROBAN | argatroban | INJECTABLE; INJECTION | 020883 | Jun 30, 2000 | RX | Yes | <disabled> | PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pfizer | ARGATROBAN | argatroban | INJECTABLE; INJECTION | 020883 | Jun 30, 2000 | RX | Yes | 5,214,052 | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc
